LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

REVOLUTION Medicines Inc

Închisă

SectorSănătate

39.52 0.3

Rezumat

Modificarea prețului

24h

Curent

Minim

38.52

Maxim

40

Indicatori cheie

By Trading Economics

Venit

-19M

-213M

EPS

-1.13

Angajați

616

EBITDA

-24M

-237M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+77.53% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

216M

7.8B

Deschiderea anterioară

39.22

Închiderea anterioară

39.52

Sentimentul știrilor

By Acuity

25%

75%

54 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 mai 2025, 22:52 UTC

Câștiguri
Principalele dinamici ale pieței

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mai 2025, 20:37 UTC

Top știri
Câștiguri

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mai 2025, 23:14 UTC

Top știri

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mai 2025, 22:46 UTC

Top știri
Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 21:58 UTC

Câștiguri

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mai 2025, 21:24 UTC

Câștiguri

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mai 2025, 20:54 UTC

Market Talk
Câștiguri

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mai 2025, 20:54 UTC

Câștiguri

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mai 2025, 20:51 UTC

Câștiguri

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 mai 2025, 20:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mai 2025, 20:50 UTC

Câștiguri

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mai 2025, 20:26 UTC

Top știri

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mai 2025, 20:25 UTC

Câștiguri

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

77.53% sus

Prognoză pe 12 luni

Medie 70.09 USD  77.53%

Maxim 80 USD

Minim 57 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

12

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

40.67 / 41.96Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

54 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.